Alternatively, it has been demonstrated that anti-CTLA-4 antibodyinhibits the suppressive activity of Tregs in patients with malignant melanoma.Effective reduction in tumor mass was shown in approximately 20% of patients.Interestingly, reduction of tumor size was linked to the development of severe,but manageable, autoimmune syndromes [41–44]. Here, CTLA4 is linked to melanoma.